All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.

2024-08-07T11:47:52.000Z

Sonelokimab for psoriatic arthritis: Results from the phase II ARGO trial

Aug 7, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in psoriatic arthritis.

The phase II ARGO trial (NCT05640245) is assessing the safety and efficacy of sonelokimab, a dual-inhibitor of interleukin (IL)-17A and IL-17F, in patients with active psoriatic arthritis.1 Topline results from this trial were reported previously by the Psoriasis and Psoriatic Arthritis Hub. Week 12 results from this trial were presented at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress by McInnes.1

Key learnings:

The primary endpoint was met; at Week 12, a greater proportion of patients treated with either sonelokimab 60 mg (n = 41) or 120 mg (n = 43) with induction achieved a 50% improvement in American College of Rheumatology score (ACR50) vs placebo (46.3% and 46.5% vs 20.0%; p < 0.05 and p < 0.01, respectively).

Additionally, at Week 12, more patients treated with sonelokimab achieved an ACR20 and Psoriasis Area and Severity Index 90 response vs placebo; this onset of response was rapid, with improvements observed by Week 4.

Sonelokimab was well tolerated, with no new safety signals.

Improvements in patient disease impact scores were observed at Week 12 with sonelokimab vs placebo, depicting an improvement in quality of life with both doses of sonelokimab.
Results indicate that sonelokimab is a promising therapy for patients with active psoriatic arthritis and support further phase III trials to assess the potential of this treatment.


  1. McInnes IB. Efficacy and safety of sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody®, in patients with active psoriatic arthritis (PsA): Results from the global, randomized, double-blind, placebo-controlled Phase 2 ARGO trial. Abstract #OP0195. Presented at: European Alliance of Associations for Rheumatology Congress 2024. June 12–15, 2024; Vienna, AT.

Your opinion matters

HCPs, what is your preferred format for educational content on the PsOPsA Hub?
9 votes - 65 days left ...

Newsletter

Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox